SHANE LIDDELOW

PRINCIPAL INVESTIGATOR

shane.liddelow@nyulangone.org | @LiddelowSA

Shane gained his Bachelors of Science (Hons) and Biomedical Science from the University of Melbourne, Australia, majoring in Neuroscience and Anatomy & Cell Biology. He received his PhD with Katarzyna Dziegielewska and Norman Saunders in Pharmacology also from the University of Melbourne. His graduate work focused on the protective barriers of the brain during early development, specifically investigating ways to augment this system for delivery of drugs to the central nervous system.

As a postdoctoral fellow in the lab of Ben Barres at Stanford University his research focused on astrocytes, the major glial subtype in the brain. He discovered a subtype of reactive astrocytes that release a toxic factor that kills specific subtypes of neurons and are present in brains of patients with Alzheimer’s, Parkinson’s, Huntington’s disease, and Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease), as well as in Multiple Sclerosis.

Shane was a recipient of the NHMRC (Australia) CJ Martin Training Award (2012-2016) and the Glenn Foundation award for Aging in 2016. He has also received the Inge Grundke-Iqbal Award for the most impactful study published in Alzheimer’s research during the previous two calendar years from the Alzheimer’s Association (2019), the David Hague Early Career Investigator of the Year Award from the Alzheimer’s Research UK (2020), and the Janett Rosenberg Trubatch Career Development Award from the Society for Neuroscience (2021).